Cochrane · systematic review · CD004706

Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer

Lawrie, TA, Winter‐Roach, BA, Heus, P, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library

Gynaecological, Neuro-oncology and Orphan Cancer2 versionsAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 1 · 20%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 4 · 80%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Current version only

Summary of main findings

Population: women with stage I/II epithelial ovarian cancer

CD004706.PUB5 (current) · 5 questions

Outcome	Effect	Evidence	Status / GRADE
Overall 5‐year survival1	no estimate extracted	1008 participants	High
Progression‐free 5‐year survival2	no estimate extracted	1170 participants	High
Overall 10‐year3 survival	no estimate extracted	925 participants	High
Progression‐free 10‐year survival4	no estimate extracted	925 participants	High
Adverse events	no estimate extracted	NR	No studies

Comparison

Population: women with stage I/II epithelial ovarian cancer

CD004706.PUB4 · 8 questions

Outcome	Effect	Evidence	Status / GRADE
Overall 5‐yr survival	no estimate extracted	1006 participants	High
Overall 10‐yr survival	no estimate extracted	925 participants	High
Progression‐free 5‐yr survival	no estimate extracted	1170 participants	High
Progression‐free 10‐yr survival	no estimate extracted	925 participants	High
Overall 5‐yr survival: sub‐optimal staging*	no estimate extracted	772 participants	High
Progression‐free 5‐yr survival: sub‐optimal staging**	no estimate extracted	934 participants	High
Overall 5‐yr survival: optimal staging*	no estimate extracted	234 participants	Moderate Downgraded: inconsistency
Progression‐free 5‐yr survival: optimal staging**	no estimate extracted	234 participants	Moderate Downgraded: inconsistency